Coronavirus, COVID-19 & Clinical Research: an overview

Last updated: 31 March 2020, 2:58 AM (CET)

The overview below originates from the ‘Nieuwsbrief voor Goede Onderzoekspraktijken (#110, 15 March 2020)‘ (translation: Newsletter for Good Research Practices) and supplemented by information that has since become available on the internet. As developments regarding COVID quickly follow, the content of this page may be outdated tomorrow. As soon as new information is available it will be added to this page. If there are important links missing, or if you have found any broken links, please contact me by using the contact form. In the case of important developments for the Netherlands, I will share them with my subscribers via a separate notification message. More information, click here (in Dutch). Do you have any additions or suggestions? Send an email to covid@bontrop.com

Onderstaand overzicht is overgenomen uit de ‘Nieuwsbrief voor Goede Onderzoekspraktijken‘nr. 110 van 15 maart 2020 en aangevuld met informatie die ondertussen beschikbaar is gekomen op internet. Het betreft uiteraard een tijdsopname en informatie kan morgen alweer achterhaald zijn. Zodra er nieuwe informatie beschikbaar is zal deze worden toegevoegd aan deze pagina. Als u belangrijke informatie en/of verwijzing mist dan kunt u die met mij delen via het contact formulier. Mochten er voor Nederland belangrijke ontwikkelingen zijn dan zal ik dat met mijn abonnees delen via een apart notificatie bericht. Meer informatie, klik hier. Heeft u een aanvulling of suggesties? Stuur een e-mail naar covid@bontrop.com Ook interessant: ‘Gezien bij Op1: Paul Elbers over de inzet van AI tegen COVID-19‘ en ‘Voor Nederland bruikbare guidance voor mensgebonden onderzoek in verband met COVID-19‘.

Content

• Public consultations
• European Union & Global
• Countries/EU Member States
• Organizations, Professional Associations
• Clinical trials
• Biobanking, Patient Registries, Research Networks
• Resources
• Grants
• Other news
• Webinars

Missing important links or found any broken links? Please use this form to report broken/missing links.

---

Public consultations

European Medicines Agency

• Points to consider on implications of Coronavirus disease (COVID-19) on methodological aspects of ongoing clinical trials
  Consultation dates: 25 March 2020 to 25 April 2020
  Click here to download

---

European Union & Global

CEN CENELEC

• CEN and CENELEC make European standards available to help prevent the COVID-19 contagion (20 March 2020).

European Centre for Disease Prevention and Control

• ECDC: Latest information on COVID-19
• ECDC Website

European Commission

• Coronavirus research
• European Commission research actions on Coronavirus (Coronavirus factsheet) (March 2020).
• Coronavirus response: Public health

European Council

• Conclusions by the President of the European Council following the video conference on COVID-19 (10 March 2020).

European Data Protection Board

• Statement on the processing of personal data in the context of the COVID-19 outbreak (20 March 2020).
• Statement of the EDPB Chair on the processing of personal data in the context of the COVID-19 outbreak (16 March 2020).
• EDPB Clarifies Privacy Rules for COVID-19 (17 March 2020). LexBlog.
• EDPB Chair Issues Statement on Data Protection and COVID-19 (16 March 2020). LexBlog.
• Coronavirus and Data Protection: Europe’s Data Protection Authorities’ Views (16 March 2020). LexBlog.
• Coronavirus and data protection –Guidance by data protection authorities (Last updated: 16 March 2020). Hogan Lovells.

European Data Protection Supervisor

• EDPS Letter Monitoring spread of COVID-19 (25 March 2020).
• EDPS Publishes Letter Addressing Coronavirus and Monitoring Location Data (27 March 2020). Privacy & Information Security Law Blog.

European Medicines Agency

• Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) pandemic.
• Guidance to sponsors on how to manage clinical trials during the COVID-19 pandemic (20 March 2020).
• EMA Offers Guidance on Conducting Trials During the COVID-19 Pandemic (20 March 2020). Regulatory Focus.
• Call to pool research resources into large multi-centre, multi-arm clinical trials to generate sound evidence on COVID-19 treatments (19 March 2020).
• First regulatory workshop on COVID-19 facilitates global collaboration on vaccine development (18 March 2020).
• COVID-19: developers of medicines or vaccines to benefit from free scientific advice (13 March 2020).
• Coronavirus disease (COVID-19).

European Network for Health Technology Assessment (EUnetHTA)

• EUnetHTA Response to COVID-19 (24 March 2020).

European Network of Centres for Pharmacoepidemiology and Pharmacovigilance

• EU PAS Register

EMA and the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) encouraged all researchers to register their pharmacoepidemiological studies related to the COVID-19 pandemic in the EU PAS Register. They should also upload and make their study protocols public, with a description of the data collected or planned to be collected. This is to facilitate collaborations and speed up the design of observational studies by others. Researchers should include ‘COVID-19’ in the study title to allow easy retrieval of all COVID-19-related studies via the ‘Title of Study’ search filter.
– Bron: EMA

Heads of Medicines Agencies

• Link to National guidance on CT management during the COVID-19 pandemia

International Coalition of Medicines Regulatory Authorities (ICMRA)

• Global regulators map out data requirements for phase 1 COVID-19 vaccine trials (24 March 2020).
• Summary Report Global regulatory workshop on COVID-19 vaccine development (18 March 2020).

A virtual meeting, held under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA), convening experts from medicines regulatory authorities, the World Health Organisation (WHO) and the European Commission.

• Global regulators map out data requirements for phase 1 COVID-19 vaccine trials (24 March 2020). EMA.
• ICMRA Plots Data Requirements for Phase I COVID-19 Vaccine Studies (24 March 2020). Regulatory Focus.
• FDA and EMA Collaborate to Facilitate SARS-CoV-2 Vaccine Development (23 March 2020). FDA.
• First regulatory workshop on COVID-19 facilitates global collaboration on vaccine development (18 March 2020).

World Health Organization

• Ethical standards for research during public health emergencies: Distilling existing guidance to support COVID-19 R&D.
• Coronavirus disease (COVID-2019) R&D
• Global research on coronavirus disease (COVID-19)
• Coronavirus disease (COVID-19) technical guidance
• Guidance for laboratories shipping specimens to WHO reference laboratories that provide confirmatory testing for COVID-19 virus: interim guidance (2 March 2020)
• Laboratory testing for coronavirus disease (‎‎COVID-19)‎‎ in suspected human cases: interim guidance (19 March 2020)
• Laboratory biosafety guidance related to coronavirus disease (‎COVID-19)‎: interim guidance (19 March 2020)
• Laboratory testing of human suspected cases of novel coronavirus (‎‎‎‎‎‎‎‎nCoV)‎‎‎‎‎‎‎‎ infection: interim guidance (10 January 2020)
• Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected, Interim guidance (13 March 2020).

Missing important links or found any broken links? Please use this form to report broken/missing links.

---

Countries & EU Member States

Netherlands

• CBG: Oproep EMA: werk samen in onderzoek naar medicijnen tegen corona (20 March 2020).
• CBG: Updates: Medicijnen tegen coronavirus en beschikbaarheid van andere medicijnen
• CCD: Coronamaatregelingen en projectbeoordeling (23 March 2020).
• CCMO: Versnelde procedure (fast track) beoordeling onderzoeksdossiers coronavirus (27 March 2020).
• CCMO: Fast-trackprocedures bij METC’s (26 March 2020).
• CCMO: Vanaf vrijdag 20 maart alleen digitale indiening (19 March 2020).
• CCMO: Verplichting natte handtekening op besluiten tot nader order opgeschort (19 March 2020).
• CCMO: UPDATE: Bereikbaarheid CCMO als gevolg van uitbraak coronavirus (19 March 2020).
• CCMO: Informatie CCMO naar aanleiding van uitbraak coronavirus.
• CCMO: Versnelde procedure (fast track) beoordeling onderzoeksdossiers coronavirus (13 March 2020)
• CCMO: Advies voor de uitvoering van klinisch onderzoek ten tijde van de beperkende maatregelen door het coronavirus (13 March 2020)
• IGJ: Coronavirus: gevolgen voor GMP- en GDP-inspecties en -certificaten (21 March 2020).
• IGJ: Coronavirus: impact op medisch-wetenschappelijk onderzoek met mensen (20 March 2020).
• IGJ: Meldpunt bij IGJ ook in het weekend open (20 March 2020)
• Ministerie IenW: Regeling van de Minister van Infrastructuur en Waterstaat van 28 maart 2020, nr. IENW/BSK-2020/57427, houdende spoedmaatregelen met betrekking tot gentherapie ter bestrijding van COVID-19 (Tijdelijke regeling afwijkende behandeling vergunningaanvragen gentherapie in verband met bestrijding COVID-19). Staatscourant (30 March 2020).
• Ministerie VWS: PowerPoint presentatie update coronavirus (24 March 2020).
• RIVM: Coronavirus kaart van Nederland per gemeente
• RIVM: Informatie over coronavirus (COVID-19) voor zorgprofessionals
• Medical Research Ethics Committee (MREC)
  • METC AMC: Spoedprocedure COVID-19 onderzoek
  • CMO Arnhem/Nijmegen Uitbraak coronavirus
  • MEC-U
  • METC Erasmus MC Veelgestelde vragen over het coronavirus
  • METC Leiden-Den Haag-Delft (LDD): CCMO Coronavirus update o.a. voor uitvoering klinisch onderzoek
  • METC Utrecht Coronavirus: tijdelijk aangepaste procedures
  • METC VUmc

Belgium

• AFMPS: Addendum to the Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) pandemic
• AFMPS: Coronavirus: Belgische richtsnoer voor het beheer van klinische proeven tijdens de coronaviruspandemie
• AFMPS: Richtlijn voor rechtstreekse aflevering van geneesmiddel aan patiënt in klinisch proef (16 March 2020)
• AFMPS: COVID-19: elektronische indiening van dossiers (14 March 2020)
• Covid-19 – 1. Belgium: Addendum to EU Guidance on Management of Clinical Trials | 2. Europe: EMA Public Consultation on Ongoing Clinical Trials (26 March 2020).
• Via BeCRO: COVID-19 impact on clinical trials, please find hereby communication from the agency (13 March 2020)
• (Research) Ethics Committee
  • Ethics Committee Research UZ/KU Leuven: COVID-19 Advice EC Research
• GDPR
  • GBA: COVID-19 en de verwerking van persoonsgegevens op de werkvloer.
  • Belgium: Public Health and Data Privacy are Not Incompatible (16 March 2020). LexBlog.
  • Belgian Supervisory Authority Issues Guidance on Data Protection and Coronavirus (16 March 2020). LexBlog.

Austria

• BASG: Clinical studies and COVID-19

Australia

• COVID-19: Guidance on clinical trials for institutions, HRECs, researchers and sponsors

Bulgaria

• Recommendations to the Sponsors for managing of Clinical Trials during the COVID-19 pandemic and the declared State of emergency in the Republic of Bulgaria

Canada

• Management of clinical trials during the COVID-19 pandemic: Notice to clinical trial sponsors.

Czech Republic

• Opinion of SÚKL’s Department of Clinical Trials on Medicinal Products on Ongoing Clinical Trials and To-Be-Commenced Clinical Trials in Light of the COVID-19 Epidemiological Situation

Croatia

• Smjernice Ministarstva zdravstva vezano uz provođenje kliničkih ispitivanjaza vrijeme pandemije bolesti COVID-19 v.1

Denmark (via Jon I. Bergsteinsson)

• Lægemiddelstyrelsen: COVID-19: Danish Medicines Agency puts inspection and control tasks on hold (26 March 2020).
• Lægemiddelstyrelsen: Extraordinary measures for clinical trials due to COVID-19 / Ekstraordinære tiltag i kliniske forsøg under COVID-19 (13 March 2020)

Estonia

• Ravimiamet: Guidance on clinical trial management in the context of COVID-19 pandemic

Finland

• FIMEA: Clinical trials during the coronavirus epidemic (COVID-19)

France

• ANSM: Covid 19 – Ongoing clinical trials
• GDPR
  • CNIL: Coronavirus (Covid-19) : les rappels de la CNIL sur la collecte de données personnelles.
  • Recommendations by the CNIL in the Context of COVID-19 (16 March 2020). LexBlog.
  • France Offers Guide for Processing COVID-19 Related Data Under GDPR (9 March 2020). LexBlog.

Germany

• BFArM: Klinische Prüfungen während der COVID-19 Pandemie
  Hinweise zur Genehmigung und Durchführung klinischer Arzneimittelprüfungen während der COVID-19 Pandemie
•  GDPR
  • BfDI: Datenschutzrechtliche Informationen zur Verarbeitung von personenbezogenen Daten durch Arbeitgeber und Dienstherren im Zusammenhang mit der Corona-Pandemie.
  • German Authorities Issue Guidance Related to Coronavirus (17 March 2020). LexBlog.

Greece

• National Organization for Medicines

Hungary

• OGYÉI: Information on the continuity of clinical trials under COVID-19 (coronavirus)
• OGYÉI: Koronavírus

Ireland (via John Hutchinson)

• HPRA: Guidance on the Management of Clinical Trials during COVID-19 (Coronavirus).

Italy (via Jon I. Bergsteinsson)

• AIFA: Sperimentazioni cliniche – COVID-19 (overview of guidance documents)
• AIFA: Notice – Clinical trials’ management in Italy during the COVID-19 (coronavirus disease 19) emergency.
• Gestione degli studi clinici in Italia in corso di emergenza COVID-19 (coronavirus disease 19) (12 March 2020).
• The Italian Medicines Agency publishes Guidance on the management of clinical trials in Italy during the COVID-19 emergency (30 March 2020). LexBlog.
• AIFA provides guidance on critical aspects relating to the management of clinical trials in Italy during the COVID-19 emergency (13 March 2020). Hogan Lovells.
• GDPR
  • Garante per la protezione dei dati personali: Coronavirus: Garante Privacy, no a iniziative “fai da te” nella raccolta dei dati Soggetti pubblici e privati devono attenersi alle indicazioni del Ministero della salute e delle istituzioni competenti.

Latvia

• ZVA: Potential changes in the conduct of clinical trials in relation to COVID-19
• ZVA: Iespējamās izmaiņas klīnisko pētījumu veikšanā saistībā ar COVID-19

Malta

• Malta Medicines Authority

Norway

• Statens legemiddelverk (NoMA): Management of Clinical Trials in relation to covid-19.

Poland

• Komunikat Prezesa z dnia 19 marca 2020 r. w sprawie badań klinicznych prowadzonych w warunkach pandemii

Portugal

• Infarmed: COVID-19
• Infarmed: Ensaios clínicos

Romania

• AMNDMR: In atentia Companiilor care desfasoara studii clinice (25 March 2020).
• AMNDMR: In atentia companiilor care desfasoara studii clinice in Romania.

South Africa

• SAHPRA Policy on Conduct of Clinical Trials of Health Products during the current COVID-19 Pendemic

Slovakia (via John Hutchinson)

• Mimoriadne opatrenia pre klinické skúšania v dôsledku COVID-19 (16 March 2020).
• ŠÚKL: Usmernenie – výdaj skúšaných liekov pacientom v klinickom skúšaní počas mimoriadnej situácie COVID – 19 (13 March 2020).
• ŠÚKL: Extraordinary measures for clinical trials due to COVID-19.

Slovenia

• JAZMP: Koronavirus (COVID-19) – obvestilo glede poslovanja JAZMP (13 March 2020).

Spain

• AEMPS: Última información de la AEMPS acerca del COVID-19.

Switzerland

• Swissmedic: Joint Guidance of Swissmedic and swissethics on the management of clinical trials with medicinal drug products in Switzerland during the COVID-19 pandemic

United Kingdom

• NHS: Timelines for fast-track review during the COVID-19 pandemi
• NHS: COVID-19: Guidance for sponsors, sites and researchers (v2.2 26 March 2020)
• NHS: Pharmacy and Radiation Assurance for COVID-19 studies
• NHS: Research in the NHS during the COVID-19 pandemic
• MHRA – Guidance
  • Guidance – Managing clinical trials during Coronavirus (COVID-19)
  • Guidance – Clinical trials applications for Coronavirus (COVID-19)
  • Guidance – Medical devices clinical investigations during the coronavirus (COVID-19) outbreak
  • Guidance for Good Laboratory Practice (GLP) facilities in relation to coronavirus (COVID-19)
  • Guidance Good laboratory practice (GLP) for safety tests on chemicals
  • Collection – MHRA guidance on Coronavirus (COVID-19)
• MHRA – Other
  • MHRA Good Practice (GxP) inspections during the COVID19 outbreak (23 March 2020).
  • Guidance on Coronavirus (20 March 2020).
  • New arrangements for MHRA Good Practice (GxP) inspections due to coronavirus (COVID-19) (20 March 2020).
  • Advice for Management of Clinical trials in relation to Coronavirus (12 March 2020)
• Public Health England: Guidance COVID-19: safe handling and processing for samples in laboratories.
• GDPR
  • ICO: Data protection and coronavirus: what you need to know
  • ICO: Data protection and coronavirus (12 March 2020).

United States

• CDC: Information for Laboratories
• CDC: Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19)
• CDC: Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)
• FDA: FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic
• FDA: Coronavirus Disease 2019 (COVID-19) Update: Foreign Inspections (10 March 2020).
• FDA: Coronavirus Disease 2019 (COVID-19)

FDA recognizes that the COVID-19 pandemic may impact the conduct of clinical trials of medical products. Challenges may arise, for example, from quarantines, site closures, travel limitations, interruptions to the supply chain for the investigational product, or other considerations if site personnel or trial subjects become infected with COVID-19. FDA has issued guidance for industry, investigators, and IRBs. The guidance is intended to provide general considerations to assist in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
– FDA, 18 March 2020

• Conducting a Clinical Trial Amidst the COVID-19 Pandemic? FDA Issues Guidance to Help Sponsors with Decision-making to Overcome Challenges (18 March 2020). FDA Law Blog.
• FDA Provides Welcome Guidance for Clinical Trials During COVID-19 (19 March 2020). BioSpace.
• FDA Releases Guidance on Clinical Trial Conduct During COVID-19 Pandemic (19 March 2020). Covington.
• NIH: Coronavirus (COVID-19)

Missing important links or found any broken links? Please use this form to report broken/missing links.

---

Organizations, Professional Associations, Research networks

Association of Clinical Research Organizations (ACRO)

• Considerations to Support Clinical Trial Monitoring Oversight During COVID-19 (13 March 2020).
• ACRO’s Recommendations in order to Support Clinical Trial Monitoring Oversight During COVID-19
• The Global Clinical Research Industry’s Commitment to Collaboration during the COVID-19 Pandemic (17 March 2020).
• COVID-19 Resource Center

Associatie van Contract Research Organisaties in Nederland (ACRON)

• Klinisch onderzoek ten tijde van de coronacrisis (25 March 2020).

ACRP

• COVID-19 News & Resource Center

Coalition for Epidemic Preparedness Innovation

• CEPI’s response to COVID-19

Cochrane

• Cochrane: Coronavirus (COVID-19) – Cochrane resources and news
• An update on Cochrane’s COVID-19 response (18 March 2020).

Combacte

• COMBACTE: Statement: PREPARE Activated to Mode 3 as Novel Coronavirus Cases in Europe are Rapidly Increasing (4 March 2020).

European Federation of Pharmaceutical Industries and Associations (EFPIA)

• Europe’s COVID-19 battle. Supply, support and the search for diagnostics, vaccines, treatments and cures (17 March 2020).
• EFPIA update on research-based pharmaceutical industry response to COVID-19 (11 March 2020).
• European pharmaceutical industry response to COVID-19 (25 February 2020).

European CRO Federation (EUCROF)

• CORONAVIRUS and Clinical Trials – Advice requested from EMA (13 March 2020)

European Organisation for Research and Treatment of Cancer (EORTC)

• Covid-19 update: Patient safety is paramount (17 March 2020).

Global Research Collaboration for Infectious Disease Preparedness (GloPID-R)

• Making the rapid research response to COVID-19 possible (17 March 2020).

Health-RI

• Call for COVID-19 data initiatives (26 March 2020).
• Health-RI facilitating COVID-19 research.Dutch Covid-19 Research Data Support Programme. (26 March 2020).

Internation Federation of Pharmaceutical Manufacturers & Associations (IFPMA)

• Global Biopharmaceutical Industry pulling out all the stops to address Coronavirus public health crisis (19 March 2020).

International Pharmaceutical Federation (FIP)

• Coronavirus SARS-CoV-2/COVID-19 pandemic: Information and interim guidance for pharmacists and the pharmacy workforce

Society for Clinical Data Management (SCDM)

• COVID-19 & Risk-areas and potential impact to clinical data. SCDM.

Society for Clinical Research Sites

• SCRS COVID-19 Resource Center

Society of Critical Care Medicine

• Critical Care for the Non-ICU Clinicians – Free Training for Non-ICU Clinicians

TransCelerate

• COVID-19

Missing important links or found any broken links? Please use this form to report broken/missing links.

---

Clinical trials

Centre for Evidence-Based Medicine (CEBM)

• CEBM: Oxford COVID-19 Evidence Service
• CEBM: COVID-19 Registered Trials – and analysis (17 March 2020).

EU Clinical Trials Register

• Clinical trials for COVID-19

National Institute for Health Research (NIHR)

• Innovation Observatory – COVID-19 Updates – daily updates in the dashboard below of clinical trials in the pipeline for potential Coronavirus (COVID-19) treatments

Nederlands Trial Register

• Trials for COVID
  The search function of NTR is not so accurate. Search results also shows trials not associated with COVID-19.

Outcomes

• COVID-19 Core Outcomes – An international initiative to establish critically important core outcomes for trials in COVID-19

Trial Insights exclusive on Scientist.com

• Portfolio Summary: Covid-19 OR Coronavirus
• Trial Insights Data Sources

TrialScope

• Corona Clinical Trials (advanced search)

Vivli

• Vivli: A global clinical research data sharing platform
• Share your COVID-19-related Trials on the Vivli Portal

WHO International Clinical Trials Registry Platform (ICTRP)

• WHO ICTRP Search Portal
  To view the COVID-19 trials worldwide, you must enter the search term ‘Covid-19’ in the search field.

Overige ontwikkelingen

• EuropaBio: Clinical Trials and Coronavirus
• NIH Clinical Trial of Investigational Vaccine for COVID-19 Begins (16 March 2020). National Institute of Health.
• Sanofi and Regeneron begin global Kevzara® (sarilumab) clinical trial program in patients with severe COVID-19 (16 March 2020).

Missing important links or found any broken links? Please use this form to report broken/missing links.

---

Biobanking, Patient Registries

BBMRI-ERIC

• BBMRI-ERIC Directory (biobank explorer)
• BBMRI-ERIC response to COVID-19: Resources from biobanks across Europe available for research on COVID-19. BBMRI-ERIC, via LinkedIn.
• BBMRI-ERIC response to the coronavirus pandemic. Resources from biobanks across Europe available for research on COVID-19 (19 March 2020).

CAPACITY registry

• European registry of patients with COVID-19 including cardiovascular risk and complications.

Covid19 Challenge.eu

• Covid19Challenge.eu – A platform for open research on large Covid-19 imaging datasets

Lean European Open Survey on SARS-CoV-2 Infected Patients

• LEOS: Studying SARS-CoV-2 in European patients
• COVID-19: Set Up of European Registry for Coronavirus Patients (19 March 2020). German Center for Infection Research (DZIF).

Society of Critical Care Medicine (SCCM)

• Viral Infection and Respiratory Illness Universal Study: COVID-19 Registry and Validation of Critical Care Data Dictionary (C2D2) (VIRUS study). Prospective, cross-sectional, observational study and registry.

UKCRC Tissue Directory and Coordination Centre

• Response to COVID-19

Missing important links or found any broken links? Please use this form to report broken/missing links.

---

Resources

Artificial Intelligence/Kunstmatige Intelligentie

• Gezien bij Op1: Paul Elbers over de inzet van AI tegen COVID-19 (25 March 2020). Vincent Bontrop (website/blog).
• Mapping the Landscape of Artificial Intelligence Applications against COVID-19 (25 March 2020). arXiv:2003.11336 [cs.CY].
• AI en covid-19: Een pandemie mag geen excuus zijn voor ‘function creep’ (26 March 2020). Kenniscentrum Data & Maatschappij.
• Responsible AI in times of pandemic (20 March 2020). Virginia Dignum, via LinkedIn.
• To fight the coronavirus pandemic effectively we need lots more data (18 March 2020). New Scientist.
• Phones Could Track the Spread of Covid-19. Is It a Good Idea? (15 March 2020). Wired.
• How Artificial Intelligence is Aiding the Fight Against Coronavirus (13 March 2020). Center for Data Innovation.
• How digital humanities can help in a pandemic (20 March 2020). EPFL.

Biobanking and biospecimines

• CDC: Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)
• CDC: Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19)
• University of California San Francisco: COVID-19 Biospecimen Guidelines (15 March 2020).
• WHO: Guidance for laboratories shipping specimens to WHO reference laboratories that provide confirmatory testing for COVID-19 virus: interim guidance (2 March 2020).
• WHO: Laboratory testing for coronavirus disease (‎‎COVID-19)‎‎ in suspected human cases: interim guidance, (19 March 2020)
• WHO: Laboratory biosafety guidance related to coronavirus disease (‎COVID-19)‎: interim guidance (19 March 2020)
• WHO: Laboratory testing of human suspected cases of novel coronavirus (‎‎‎‎‎‎‎‎nCoV)‎‎‎‎‎‎‎‎ infection: interim guidance (10 January 2020)

Clinical research resources

• ISARIC: COVID-19 Clinical Research Resources
• The Global Health Network: Kownledge Hub Coronavirus Outbreak
• WIRB-Copernicus Group: Resource Center: COVID-19 and Clinical Trial Operations

Clinical Research Organisations

• COVANCE: Coronavirus (COVID-19) Update
• Delta Healthcare Consulting: Covid-19 – Clinical Trial Rescue (16 March 2020). (‘visit subject at home‘)
• ICON: COVID-19 CEO Letter
• Medidata: COVID-19 Regulatory Developments Impacting Technology Use in Clinical Trials (23 March 2020).
• Medidata: COVID 19 and Clinical Trials: The Medidata Perspective (23 March 2020).
• Robarts Clinical Trials: RCTI Covid-19 Sponsor Update (26 March 2020).

Courses, Educative

• COVID-19: What You Need to Know
• Imperial College London & Coursera: Free COVID-19 online course re-launches to learners worldwide.
• JoVE: Coronavirus Free Access Resource Center

Communication and digital solutions

• ICT & health: Overzicht Oplossingen
• NHG: Corona – inzet van digitale communicatiemiddelen en applicaties
• Siilo: How Users are Working with Siilo to Address Covid-19
• Signal: Signal, for messages and calls
• SURFdrive: Persoonlijke cloudopslagdienst voor het Nederlandse onderwijs en onderzoek
• What You Should Know About Online Tools During the COVID-19 Crisis (19 March 2020). EFF.

Data management

• COVID-19 & Risk-areas and potential impact to clinical data. SCDM.
• COVID-19 | Data Management| Impact on Clinical Database & DMPs (19 March 2020). David Edghill, via LinkedIn.

Data Networks and research

• ELIXIR’s services to support COVID-19 research (24 March 2020).
• ELIXIR support for SARS-CoV-2 research
  As the ESFRI Research Infrastructure for life science data, ELIXIR Nodes provide a range of services that can be used by researchers and consortia working on SARS-CoV-2 research.
• GO FAIR Foundation: Virus Outbreak Data Network (VODAN)
  • ZonMw: Start datanetwerk coronavirus (13 March 2020).
• Hohns Hopkins CSSE: 2019 Novel Coronavirus Visual Dashboard (data repository in GitHub).
• Health Data Research UK: Coronavirus (COVID-19) Useful Resources (GitHub)
• Kaggle: Help us better understand COVID-19
• Kaggle: COVID-19 Open Research Dataset Challenge (CORD-19)
  An AI challenge with AI2, CZI, MSR, Georgetown, NIH & The White House
• Medium – Towards data science: 5 Datasets About COVID-19 you can Use Right Now (27 March 2020).
• Tableau: COVID-19 Data Hub
  • How Tableau is making real-time COVID-19 data accessible to everyone (27 March 2020). TechRepublic.

Diagnostics, Genomics, Viral strains

• European Virus Archive: Wuhan coronavirus
• GenBank: SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) Sequences
• Icahn School of Medicine at Mount Sinai – The Krammer Laboratory: COVID-19
• Nextstrain: Genomic epidemiology of novel coronavirus
• Terra: Broad scientists release COVID-19 best-practices workflows and analysis tools in Terra (18 March 2020).
• Terra: COVID-19 workspaces, data and tools in Terra (17 March 2020).

Electronic Data Capturing

• Castor EDC: Castor vs. the Coronavirus (COVID19) (13 February 2020)

Castor has joined the global fight against the Coronavirus by making our research data capture platform available for free for all non-profit COVID19 research projects. We have developed ready for use eCRFs based on the WHO standard CRFs, to help researchers start their study or registry in less than an hour. The lack of quality data should not be the reason for a delay in finding a cure.
– Derk Arts, 13 February 2020

Ethiek

• Beyond liberty: social values and public health ethics in responses to COVID-19 (). Nuffliec Council of Bioethics.
• The Hastings Center: Ethics Resources on the Coronavirus (COVID-19).

Hacking Health

• Dutch Hacking Health: Hack Corona!

Pharmaceutics

• Hydroxychloroquine
  • What if hydroxychloroquine doesn’t work? What if it does? Right now, we don’t know (27 March 2020). STAT.
  • Hydroxychloroquine for COVID-19: What’s the Evidence? (25 March 2020). Medscape.
  • Thoughts on the Gautret et al. paper about Hydroxychloroquine and Azithromycin treatment of COVID-19 infections Science Integrity Digest.
• Regulatory Focus: COVID-19 Vaccine Tracker
• University of Liverpool: COVID-19 Drug Interactions

Research output

• Annals of Internal Medicine COVID-19
• British Medical Journal COVID-19
• Cell COVID-19
• eLife: Peer Review: Publishing in the time of COVID-19
• Elsevier: Novel Coronavirus Information Center
• EPPI-Centre: Evidence Map COVID-19
• Google Scholar search strategy
• JAMA Network COVID-19
• Journal of Medical Virology COVID-19
• LitCovid: Curated literature hub for tracking up-to-date scientific information about the 2019 novel Coronavirus
• Medisch Contact COVID-19
• Nederlands Tijdschrift voor Geneeskunde COVID-19
• New England Journal of Medicine COVID-19
• NIH: Disaster Lit search strategy
• Open Access COVID-19
• Preprints COVID-19
• PubMed search strategy (New PubMed)
• ResearchGate: Combating COVID-19
• Science Open: COVID-19 resources on ScienceOpen: Find and share research outputs (17 March 2020).
• Semantic Scholar: CORD-19 Discourse
• Semantic Scholar: Your First Research Feed
• The Allen Institute for Artificial Intelligence: The CORD-19 explorer is a full-text search engine for the COVID-19 Open Research Dataset.
• The Allen Institute & Semantic Scholar: COVID-19 Open Research Dataset (CORD-19)
• The Lancet COVID-19
• Twitter: Search results #CORD19

Social Sciences and Humanities, Expertise

• COVID-19 Social Science Research Tracker (GitHub).
• SSH & COVID-19

SSH COVID-19 portal aims to consolidate and organize the SSH expertise across the Dutch universities in a publicly available national portal, ensuring fast and direct access to academic experts.
– Bron: SSH

Trackers & maps

• John Hopkins University: Map of global infections
• Milken Institute: COVID-19 Treatment and Vaccine Tracker
• Regulatory Focus: COVID-19 Vaccine Tracker.
• STAT: The Covid-19 Tracker
• Worldometer: COVID-19 Coronavirus Pandemic

Training

• Personal Health Train: Personal Health Train will help research on viral outbreaks (16 March 2020).

Updates

• NTvG: Dossier COVID-19
• Science Business: LIVE BLOG: R&D response to COVID-19 pandemic

Missing important links or found any broken links? Please use this form to report broken/missing links.

---

Grants

Crowdhelix Network

• Crowdhelix is seeking researchers & innovators worldwide with a strong track record of excellence in fields relevant to the global effort to tackle the novel coronavirus (COVID-19) pandemic.

European Commission, H2020

• Commission approves additional support via Horizon 2020 to strengthen priorities, including coronavirus research (25 March 2020).
• CALL: Applications welcome from startups and SMEs with innovative solutions to tackle Coronavirus outbreak
• Horizon 2020 calls be extended (17 March 2020).
• H2020: Will the deadlines for Horizon 2020 calls be extended related to the COVID-19 outbreak? (16 March 2020)
• H2020: Can the clause on “force majeure” in the Horizon 2020 grant agreement be invoked in relation to the COVID-19 outbreak? (16 March 2020)

Europen Coorperation in Science & Technology – COST

• Open call collection date – postponed until October 2020 (18 March 2020).

European Research Council

• Frontier research at the service of the coronavirus epidemic response (19 March 2020).

Funding opportunities

• Science Business: Database: Coronavirus Funding Opportunities

Funding support

• ttopstart: Corona – Funding for R&D

Health Holland

• CALL: Health Holland Special Announcement COVID-19

Innovative Medicines Initiative

• CALL: IMI2 – Call 21: Development of therapeutics and diagnostics combatting coronavirus infections

League of European Research Universities

• LERU asks for extension of H2020 Health calls (20 March 2020).

Marie Skłodowska-Curie

• Corona Virus: Consequences for Marie Skłodowska-Curie Actions (MSCA) projects and related activities (13 March 2020).

Medical Research Council

• An update for MRC funded researchers regarding the coronavirus situation (18 March 2020).

NIH

• Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients of NIH Funding.

NWO

• NWO drafts guideline for postponing primary process (17 March 2020)

UK Research and Innovation

• UPDATED March 19: Impact of Coronavirus on UKRI-supported research (19 March 2020).

Wellcome

• Wellcome pledges up to $50 million to new initiative to speed development of COVID-19 treatments (9 March 2020). Wellcome.
• Sharing research data and findings relevant to the novel coronavirus (COVID-19) outbreak (31 January 2020). Wellcome.

ZonMw

• Coronavirus
• Gevolgen COVID-19 uitbraak voor subsidierondes ZonMw (17 March 2020).
• ZonMw staakt subsidierondes (17 March 2020). Skipr.

Missing important links or found any broken links? Please use this form to report broken/missing links.

---

Other news

30 March 2020

• Debate flares over using AI to detect Covid-19 in lung scans (30 March 2020). STAT.
• Biobanks in times of a pandemic like Covid-19 (30 March 2020). Erik Steinfelder, via LinkedIn.
• Covid-19 Hastens Embrace Of Virtual Trials (30 March 2020). Clinical Leader.

29 March 2020

• WHO SOLIDARITY Trial Enrolls First Patient in Norway: The World Requests more Transparency (29 March 2020). TrialsSite News.
• Silicon Valley, Follow, Don’t Lead. Jules Polonetsky, via LinkedIn.

28 March 2020

• Federale regering en Belgische biofarma-industrie versnellen de inspanningen in de strijd tegen COVID-19 (28 March 2020). Pharma.be
• The Science of This Pandemic Is Moving at Dangerous Speeds (28 March 2020). Wired.

27 March 2020

• COVID-19 pandemic and regulatory guidelines on clinical trial conduct; similarities and differences between regions (27 March 2020). Parexel.
• How sick will the coronavirus make you? The answer may be in your genes (27 March 2020). Science.
• Transparency & Other Takeaways from COVID-19 Clinical Trials (27 March 2020). TrialScope.
• Digital technology and COVID-19 (27 March 2020). Nature.
• ‘It’s a razor’s edge we’re walking’: inside the race to develop a coronavirus vaccine (27 March 2020). The Guardian.
• Guidance from the EU EMA and UK MHRA on clinical trials during the COVID-19 Pandemic (27 March 2020). BioSlice Blog, Arnold & Porter.
• COVID-19 needs a Manhattan Project (27 March 2020). Science.

26 March 2020

• ‘Drug development is a long, long process’: pharma CEO in Italy sounds a note of caution on Covid-19 (26 March 2020). STAT.
• ‘We’re racing against the clock’: Researchers test wearables as an early warning system for Covid-19 (26 March 2020). STAT.
• Science-ing from home (26 March 2020). Nature.
• What we’ve learned about the coronavirus — and what we still need to know (26 March 2020). STAT.
• Should scientists infect healthy people with the coronavirus to test vaccines? (26 March 2020). Nature.
• Latest Guidance of the EMA and European and UK National Authorities on Crisis Management of Clinical Trials and Medicine Supplies During the COVID-19 Pandemic (26 March 2020). Arnold & Porter.
• COVID19 Expected to Impact Clinical Trials and Slow Down Drug Development (26 March 2020). ADC Review.
• Wetenschappers in verzet tegen lockdown: ‘We moeten de paniek bezweren’ (26 March 2020). Het Parool.
• What it’s like to go into the lab at a biopharma company during the coronavirus pandemic (26 March 2020). STAT.

25 March 2020

• Gezien bij Op1: Paul Elbers over de inzet van AI tegen COVID-19 (25 March 2020). Vincent Bontrop (website/blog).
• Elsevier: Infographic: global research trends in infectious disease (25 March 2020).
• Preserving Clinical Trial Integrity During the Coronavirus Pandemic. JAMA. Published online March 25, 2020.
• Covid-19 roundup: Bristol Myers suspends clinical trials, grounds field team; Vir ushers antibody candidates to human testing (25 March 2020). Endpoints News.
• COVID-19 Vaccine Test Lab Hit by Maze Ransomware (25 March 2020). LexBlog.
• Commission working on proposal to postpone MDR date of application for one year (25 March 2020). Medicaldeviceslegal.

24 March 2020

• Coronavirus te lijf met big data (24 March 2020). MUMC+
• Onderzoek met ‘big data’ naar beste behandeling coronavirus (24 March 2020). Skipr.
• Sites Increasingly Worried About Coronavirus-Related Trial Interruptions (24 March 2020). ACRP.
• Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA. Published online March 24, 2020.
• Covid-19 raakt biotech hard (24 March 2020). HollandBIO.
• DCRF buigt zich over impact corona op klinisch onderzoek (24 March 2020). Vereniging Innovatieve Geneesmiddelen.

23 March 2020

• Ethics Committee Reviews of Applications for Research Studies at 1 Hospital in China During the 2019 Novel Coronavirus Epidemic. JAMA. Published online March 23, 2020.
• Covid-19: How unprecedented data sharing has led to faster-than-ever outbreak research (23 March 2020). Horizon.
• As Covid-19 spreads, disruptions to clinical trial and drug development accelerate (23 March 2020). STAT.
• COVID-19 vaccine & therapy research boosted by six new projects in rapid response (23 March 2020). Medical Research Council.
• Pharma boss: EU will have to focus on long-term medical research ecosystem (23 March 2020). Euractiv.
• EU Guidance on Conduct of Clinical Trials During COVID-19 Pandemic and Specific Advice on Initiation of Clinical Trials for Treatments of COVID-19 (23 March 2020). Van Bael & Bellis.
• UK launches whole genome sequence alliance to map spread of coronavirus (23 March 2020). Medical Research Council.
• Academic Library Response to COVID-19: Real-Time Data Gathering and Dissemination (23 March 2020). The Scholary Kitchen.
• Covid-19 is reshaping the world of bioscience publishing (23 March 2020). STAT.

22 March 2020

• Coronavirus: How Artificial Intelligence, Data Science And Technology Is Used To Fight The Pandemic (22 March 2020). Bernard Marr, via LinkedIn.
• WHO launches global megatrial of the four most promising coronavirus treatments (22 March 2020). Science.

21 March 2020

• Hunt for coronavirus cure is making science more open (21 March 2020). University World News.
• Cardialysis: Update via LinkedIn (21 March 2020).

20 March 2020

• NIH shifts non-mission-critical laboratory operations to minimal maintenance phase (20 March 2020). NIH.
• CLAIRE: Open Letter Leveraging artificial intelligence to help manage the Covid-19 crisis.
• The coronavirus is imperiling drug studies. A virtual study of the Apple Watch could be positioned to thrive (20 March 2020). STAT.

19 March 2020

• Coronavirus lockdown: What I learnt when I shut my cancer lab in 48 hours (19 March 2020). Nature.
• 8 Significant Risks COVID-19 Poses To Clinical Trials — And How To Mitigate Them (19 March 2020). Med Device Online.
• Call To Pool Research Resources into Large Trials to Generate Evidence On COVID-19 Treatments (19 March 2020). Applied Clinical Trials.
• Biotech in the time of the coronavirus: Disruptions continue, but there’s some good news, too (19 March 2020). STAT.
• Clinical Trial Practitioners Grapple with Challenges from Pandemic (19 March 2020). ACRP.
• NVIC verwacht komende week grote toename ic-opnames door corona (19 March 2020. Medisch Contact.
• 4 principles journals can embrace to aid reproducibility of research (19 March 2020). Elsevier.
• UAntwerpen (Flanders) leads European coronavirus taskforce (19 March 2020). Flanders.bio.

18 March 2020

• How to Salvage Clinical Trials During an Epidemic (18 March 2020). ACRP.
• Desk-based Health Authority Inspections: A Risk-based Approach to Compliance (18 March 2020). Parexel.
• WHO to launch multinational trial to jumpstart search for coronavirus drugs (18 March 2020). STAT.
• FDA urges clinical researchers to go virtual in response to COVID-19 pandemic (18 March 2020). FierceBiotech.
• Coronavirus will have a ‘big impact’ on one-third of U.S. clinical trial sites, survey finds (18 March 2020). STAT.
• Clinical trial sites anticipate disruption due to Covid-19; FDA issues guidance for trials amid pandemic (18 March 2020). MedCity News.
• FDA urges virtual patient visits as coronavirus disrupts clinical trials – Reuters (18 March 2020). Reuters.
• Coronavirus led one biotech to pause a key trial, as more begin to follow (18 March 2020). BioPharma Dive.
• As Covid-19 R&D goes into overdrive, nuts-and-bolts biopharma research is hitting the skids. How bad is it? (18 March 2020). Endpoints News.
• De farmaceutische sector en de strijd tegen het COVID-19 virus (18 March 2020). Pharma.be.
• Sponsors Offer Tips to Help Maintain Trials During Coronavirus Crisis (18 March 2020). ACRP.

17 March 2020

• Syneos Health: Our Connected Community: Syneos Health Response to COVID-19 (17 March 2020).
• COVID-19 Briefing: Notes from Covington & Burling March 13 Teleconference “COVID-19: Evolving Considerations for the Life Sciences Industry” (17 March 2020). Govzilla.
• Navigating Clinical Trials in the Coronavirus Era (March 2020). Science37.
• Report sees ‘untold’ coronavirus impact on clinical research (17 March 2020). Outsourcing Pharma com.
• Effect COVID-19 op klinische studies (17 March 2020). Dutch Oncology Research Platform.
• COVID-19: Corona and Clinical Trials (17 March 2020). Trial & Eric.
• ACRO Calls for Increased Centralized Monitoring, New Guidelines to Assist Trial Conduct Amidst Corona Disruption (17 March 2020). ACRP.
• Novel coronavirus (COVID-19) (17 March 2020). IFPMA.
• A fiasco in the making? As the coronavirus pandemic takes hold, we are making decisions without reliable data (17 March 2020). STAT.

16 March 2020

• Editorial Concern—Possible Reporting of the Same Patients With COVID-19 in Different Reports. JAMA. Published online March 16, 2020.

The editors have become aware that some of the patients described in some of these manuscripts, sometimes with overlapping authorship, have been reported in more than 1 submission. This inclusion of the same patients in more than 1 report has not been clearly indicated in the submitted manuscripts. This is of concern and may represent a lapse in ethical standards of scientific reporting.
– Editorial, JAMA, 16 March 2020, doi:10.1001/jama.2020.3980

• The Risky Race for a Quick Coronavirus Vaccine (16 March 2020). The New Republic.
• The global impact of COVID-19 on clinical trials and countermeasure development (16 March 2020). Hogan Lovells.
• Publishers make coronavirus (COVID-19) content freely available and reusable (16 March 2020). Wellcome
• Recruitment platform offered free-of-charge for coronavirus clinical trials (16 March 2020). Outsourcing Pharma com.
• Kennissector gaat op slot door coronacrisis (16 March 2020). ScienceGuide.
• Pfizer schetst ‘Vijf-Punten Plan’ om COVID-19 te bestrijden (16 March 2020). Pfizer.
• COVID-19 Upends Business-as-usual Research and Regulatory Practices (16 March 2020). PharmExecCom.
• Biowetenschappen en Maatschappij Cahier: Help, ik ben besmet! (16 March 2020).

15 March 2020

• Sponsors Delay Trials and Shift Toward Using Remote Procedures (15 March 2020). CenterWatch.

14 March 2020

• Coronavirus pandemic forces some research labs to shut down, with uncertain futures for scientific projects (14 March 2020). STAT.

13 March 2020

• Elsevier gives full access to its content on its COVID-19 Information Center for PubMed Central and other public health databases to accelerate fight against coronavirus (13 March 2020).
• Data Sharing and Open Source Software Help Combat Covid-19 (13 March 2020). Wired.

12 March 2020

• Clinical Trials Feel the Coronavirus Crunch (12 March 2020). Applied Clinical Trials.
• Changes To Research Made In Response To COVID-19 (12 March 2020). Clinical Leader.

10 March 2020

• As Covid-19 Fears Mount, a Face Mask Shortage Imperils Research (10 March 2020). Undark.

6 March 2020

• How It All Started: China’s Early Coronavirus Missteps (6 March 2020). The Wall Street Journal.

4 March 2020

• Everything You Need to Know About Coronavirus Vaccines (4 March 2020). Wired.

Overige berichtgeving mbt. AVG, Bescherming persoonsgegevens, Privacy

• The Corona Effect of Shaping the Future. On Trojan Horses and ‘The New Normal’ (27 March 2020). Marlon Domingus, via LinkedIn.
• Verzameling van metadata door de Europese Commissie – noodzaak in crisistijd? (27 March 2020). Sybren Spoelstra, via LinkedIn.
• Privacy and Pandemics: A Thoughtful Discussion (27 March 2020). Future of Privacy Forum.
• Data in de strijd tegen corona – hoe zit het met de privacy? (24 March 2020). SOLV.
• UK Information Commissioner Releases COVID-19 Guidance for Controllers and Health and Care Practitioners (23 March 2020). LexBlog.
• Global Privacy Assembly Tracking Data Protection Authority Guidance on COVID-19 (23 March 2020). LexBlog.
• COVID-19, Scientific Research and the GDPR – Some Basic Principles (20 March 2020). Inside Privacy, Covington.
• Ensuring Data Security and Privacy During Coronavirus (19 March 2020). LexBlog.
• COVID-19 Update: Limited Waiver of HIPAA Sanctions and Penalties for Certain Hospitals (17 March 2020). LexBlog.
• HIPAA Privacy Rule Waiver, Other Medical Information Questions During the COVID-19 Pandemic (17 March 2020). LexBlog.
• COVID-19 Bulletin: Balancing Privacy and Public Health Needs (16 March 2020). LexBlog.
• Spanish Data Protection Authority: Protect Personal Data Without Hindering Pandemic Response (13 March 2020). LexBlog.
• Coronavirus en het medisch beroepsgeheim (13 March 2020). TeekensKarstens Advocaten.
• Coronavirus en privacy: onze tips voor werkgevers (6 March 2020). TeekensKarstens Advocaten.
• Key COVID-19 Issues for Privacy Professionals (10 March 2020). LexBlog.
• Data Protection Issues Raised by Guidance and Efforts to Prevent the Spread of COVID-19 (9 March 2020). LexBlog.
• Danish Data Authority Issues Guidance on COVID-19 Data Disclosure 9 March 2020). LexBlog.
• Norwegian Supervisory Authority Issues COVID-19 Guidance (10 March 2020). LexBlog.
• Is corona een vrijbrief om privacy te schenden? Privacylab.

Missing important links or found any broken links? Please use this form to report broken/missing links.

---

Webinars

• 30 March 2020 – Cyntegrity: Webinar Clinical Trials at Risk
  Aanvang: 6.00 CEST

• 31 March 2020 – RQA Webinar: COVID-19 ‘GxP Insights on Building Resilience and Agility’
  Aanvang: 2.00 PM CEST

• 31 March 2020 – Duke Medicine: Identifying Best Practices for Conducting Clinical Trials with the New FDA Guidance During the COVID-19 Pandemic
  Aanvang: 5.15 PM CEST

• 1 April 2020 – BBMRI.QM : Web conference – Biobanking in times of COVID-19: Risks and Opportunities for Biobanks
  Aanvang: 10.00 AM CEST

• 2 April 2020 – GCP Central: Live Webinar ‘Clinical trials during corona – a risk-based approach in the interest of patients and data’
  Aanvang: 2.30 uur PM CET

• 6 April 2020 – EFGCP: Webinar on Clinical Trials During the Corona Virus Pandemic: Pragmatic Approach to the Risks
  Aanvang: 5.00 uur PM CEST

• 7 April 2020 – Ergomed Webinar: Ensuring Continuity in Rare Disease Clinical Trials During the COVID-19 Crisis
  Aanvang sessie 1: 3.00 uur PM CET
  Aanvang sessie 2: 8.00 uur PM CET

• 8 April 2020 – Pharmaphorum & ERT: webinar Vaccines trials in the era of COVID-19 – balancing study speed, accuracy and patient experience
  Aanvang: 5.00 uur PM CET

Past webinars

• Brookwood Global: Ways to Manage Clinical Trial Challenges in a Pandemic Period (25 March 2020)
  View recording
  Download slides/notes

• 27 March 2020 – Castor EDC: Webinar: Research Continuity During COVID-19
  Aanvang: 16:00 uur CET

---

Meer nieuws? Kijk ook eens op news.bontrop.com

Abonneren op de Nieuwsbrief voor Goede Onderzoekspraktijken Kies voor een abonnement op de ‘Nieuwsbrief voor Goede Onderzoekspraktijken’ en blijf op de hoogte van actuele ontwikkelingen rond medisch-wetenschappelijk onderzoek met mensen, nieuwe wet- en regelgeving en gereviseerde richtlijnen! … Continue reading

Eerdere edities Nieuwsbrief voor Goede Onderzoekspraktijken Op deze pagina vindt u een overzicht eerdere uitgaven van de Nieuwsbrief voor Goede Onderzoekspraktijken. … Continue reading